rusfertide acetate - Profile
What are the generic sources for rusfertide acetate and what is the scope of freedom to operate?
Rusfertide acetate
is the generic ingredient in one branded drug marketed by Takeda Pharms Am and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for rusfertide acetate
Generic Entry Date for rusfertide acetate*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for rusfertide acetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-001 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-001 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-001 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-001 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-001 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-001 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-001 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for rusfertide acetate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2014232954 | ⤷ Start Trial | |
| Australia | 2018260800 | ⤷ Start Trial | |
| Canada | 2906830 | ⤷ Start Trial | |
| China | 105451755 | ⤷ Start Trial | |
| Denmark | 2968443 | ⤷ Start Trial | |
| European Patent Office | 2968443 | ⤷ Start Trial | |
| European Patent Office | 4091624 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
